Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook

Core Insights - Cerus Corporation announced preliminary product revenue for Q4 and full-year 2025, highlighting significant growth in patient access to INTERCEPT treated blood components globally [1] Group 1: Financial Performance - The company reported a remarkable year in 2025, with increased sales of kits contributing to revenue growth [1] - Specific revenue figures for Q4 and full-year 2025 were not disclosed in the announcement [1] Group 2: Future Guidance - Cerus provided product revenue guidance for 2026, indicating expectations for continued growth and milestones for the upcoming year [1]